2 news items
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
IKT
15 May 24
and development expenses was due to a decrease of $0.7 million in IkT-001 Pro expenses offset by a $0.6 million increase in Risvodetinib expenses
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
IKT
27 Mar 24
the result of an increase in investor relations costs of $1.0 million and an increase in employee costs of $0.3 million that were partly offset
- Prev
- 1
- Next